Search

The article discusses the use of the FDA-approved YAP inhibitor, Verteporfin, to enhance radiosensitivity in chordoma, a type of cancer that is resistant to radiotherapy. By inhibiting Yes-Associated Protein (YAP), Verteporfin reduces DNA damage repair proteins and genes, leading to enhanced DNA double-stranded breaks after radiation and accumulation of cells in the G2M phase. This treatment approach has shown promising results in preclinical studies, sensitizing chordoma tumors to radiation and inhibiting tumor growth. The research is available as a preprint and has not yet undergone peer review. [Extracted from the article]

A recent study from the Department of Physiology explores the potential impact of fisetin, a natural flavonoid found in fruits and vegetables, on colorectal cancer. The research suggests that fisetin may induce apoptosis in colon cancer cells through various mechanisms, affecting key cell signaling pathways and inhibiting the growth of cancer cells. These findings highlight the potential of fisetin as an adjunct therapy for colorectal cancer, particularly in cases with specific genetic mutations. For more information, readers can refer to the full article in Animal Models and Experimental Medicine. [Extracted from the article]

Researchers at Memorial Sloan Kettering Cancer Center have discovered that the body's innate immune system plays a crucial role in maintaining genome stability during DNA replication, with implications for cancer development. Chronic activation of immune pathways can contribute to tumor development in breast cancer, as shown in a study led by Dr. John Petrini. The study highlights the importance of the Mre11 complex in genome stability and the role of interferon-stimulated genes in promoting cancer, offering new insights for potential therapies. [Extracted from the article]

Researchers from the School of Health have conducted a study on the DNA damage marker g-H2AX and its potential use in disease modeling, detection, diagnosis, and prognosis, particularly in relation to cancer. The study highlights the importance of quantifying g-H2AX in various biological samples and suggests that it could be used to predict cancer risk when applied to healthy tissue and peripheral blood mononuclear cells. For more information, the full article can be accessed for free at the publisher's website. [Extracted from the article]

A study conducted at Washington University in St. Louis, Missouri, focused on the role of DNA polymerase theta (POLQ) in papillary thyroid cancers. The research found that increased POLQ expression is associated with aggressive and DNA repair-deficient thyroid cancers. The study suggests that POLQ overexpression could potentially serve as a valuable clinical marker and therapeutic target for thyroid cancer treatment. The findings were published in the journal Surgery and have been peer-reviewed. [Extracted from the article]

A study conducted at Jiangsu University in Zhenjiang, China, focused on the role of senataxin in DNA damage response (DDR) and cellular senescence. Senataxin was found to play a crucial role in repairing DNA double-strand breaks (DSBs) and determining cell fate under oxidative stress. The research suggests that senataxin may protect against the accumulation of senescent cells, potentially offering therapeutic benefits for age-related cellular decline and neurodegenerative diseases. This study highlights senataxin as a key mediator in DDR pathways and a potential target for conditions where cellular senescence contributes to disease pathology. [Extracted from the article]

A recent study published in Gastroenterology Week highlights the discovery of epigenetic silencing of the BEND4 gene as a potential marker for enhancing the efficacy of ATM inhibitors in pancreatic cancer treatment. The research delves into the role of BEND4 in DNA damage repair and its impact on tumor growth and progression. The findings suggest that targeting the ATM pathway in BEND4-silenced pancreatic cancer cells could lead to more effective treatments, offering hope for improved outcomes in a disease with historically poor survival rates. [Extracted from the article]

The article discusses the development of circular adeno-associated virus (AAV) cargos for targeted seamless integration in the liver. The research focuses on Integrase-mediated programmable genomic integration (I-PGI) as a precise approach for gene insertion without the need for DNA double-stranded breaks (DSBs). The study demonstrates the successful integration of circular AAV cargo in primary human hepatocytes (PHH) and in vivo, highlighting the potential for DSB-free programmable genomic integration using integrase and AAV cargo. [Extracted from the article]

The University of Bielefeld researcher discusses the role of the transcription factor NF-kB in Alzheimer's disease, highlighting its opposite functions in neurons and glial cells. The study emphasizes the potential involvement of NF-kB in hereditary mutations of the tumor necrosis factor pathway in AD patients, with a focus on the APOE4 allele and its impact on neuronal survival. The research suggests that NF-kB could be beneficial for healthy neurons but detrimental in Alzheimer's disease, offering potential therapeutic avenues to target glial NF-kB activation. [Extracted from the article]

The article discusses the development of radiotolerance in planarians exposed to ionizing radiation. Planarians, specifically Schmidtea mediterranea, were able to overcome the adverse effects of radiation through enhanced DNA protection and repair mechanisms. The study found that planarians exposed to higher amounts of sub-lethal radiation could adapt and recover reproductive capabilities faster than those exposed to lower amounts. The research suggests that planarians develop radiotolerance over several years of recurrent ionizing radiation exposure, surviving without apparent functional or morphological defects for an undetermined time. [Extracted from the article]

The article discusses the role of the Rho GTPase pathway in the acquisition and reversal of chemoresistance in glioblastoma (GBM) tumors. Researchers found that GBM cells resistant to certain chemotherapy drugs exhibited increased Rho pathway activity, which could be reversed by Rho GTPase inhibition. The study highlights the importance of actin cytoskeleton dynamics and Rho pathway activity in both the development and reversal of chemoresistance in GBM tumors. [Extracted from the article]

A recent study conducted by researchers at Indiana University School of Medicine focused on the impact of optimized Ku-DNA binding inhibitors on the cellular and in vivo DNA damage response in cancer cells. The study found that blocking DNA-dependent protein kinase (DNA-PK) can enhance the effectiveness of cancer treatments such as radiation therapy. The researchers developed Ku-DNA binding inhibitors (Ku-DBis) that showed promising results in making cancer cells more sensitive to radiation, particularly in non-small cell lung cancer (NSCLC) cells lacking ATM. The findings suggest the potential application of Ku-targeted inhibitors in cancer treatment. [Extracted from the article]

The article discusses the role of CHK1 in regulating the catalytic activity of TOP1 to prevent the accumulation of potentially lethal DNA double strand breaks. The study found that CHK1 phosphorylates TOP1 at Serine-320, stimulating its catalytic cycle and minimizing the accumulation of TOP1-DNA-covalent-complexes in cancer cells. The inhibition of CHK1-mediated TOP1-phosphorylation leads to replication and transcription-associated genomic instability, which may have implications for ongoing clinical trials with TOP1- and CHK1-targeting drugs. This preprint has not yet been peer-reviewed and provides valuable insights into potential therapeutic outcomes in cancer treatment. [Extracted from the article]

Researchers from the University of Texas Health Science Center have conducted studies on the causes and consequences of DNA double-stranded breaks in cardiovascular disease, specifically focusing on cardiomyopathies. The research highlights the importance of genomic stability and the impact of DNA lesions on gene expression and repair mechanisms. The study suggests that interventions to reduce the generation of DNA double-stranded breaks and enhance repair mechanisms could have beneficial effects on pathological conditions like hereditary cardiomyopathies and aging. The research has been peer-reviewed and provides valuable insights into potential therapeutic interventions for cardiovascular diseases. [Extracted from the article]

A patent has been issued for DNA-PK inhibitors by Vertex Pharmaceuticals Incorporated, focusing on the repair of DNA double-strand breaks through the Non-Homologous End Joining Pathway. The inhibitors aim to enhance the efficacy of cancer chemotherapy, radiotherapy, and genome editing systems by suppressing NHEJ enzymes like DNA-PK. This development may lead to improved treatments for cancer and increased efficiency in genome editing processes. [Extracted from the article]

The article discusses the role of endogenous neuronal DNA double-strand breaks (DSBs) in brain aging and neurodegeneration. Through a study on mice with post-developmental inactivation of the C-NHEJ core factor Xrcc4 in forebrain neurons, researchers found that the accumulation of DSBs in neurons does not significantly impact gene expression, 3-D genome organization, or mutational outcomes. Despite the aging-associated accumulation of neuronal DSBs, the study concludes that spontaneous DSBs caused by normal cellular processes are not sufficient to cause brain aging and neurodegeneration, even in the absence of C-NHEJ, the principal neuronal DSB repair pathway. [Extracted from the article]

The article discusses how gepotidacin and zolifodacin stabilize DNA-cleavage complexes with bacterial type IIA topoisomerases, specifically DNA gyrase. Quinolone antibiotics interact with the GyrA subunit, while zoliflodacin interacts with the GyrB subunit and stabilizes lethal double-stranded DNA breaks. Gepotidacin stabilizes single-stranded DNA breaks and sits between the two DNA-cleavage sites. The article proposes a single moving metal-ion catalyzed DNA-cleavage mechanism based on crystal structures of Staphlococcus aureus DNA gyrase complexes. [Extracted from the article]

A study conducted at the University of Duisburg-Essen in Germany explored the effects of the PARP inhibitor Talazoparib on cancer cells. The research found that Talazoparib effectively radiosensitizes cancer cells by shifting the repair of DNA double-strand breaks towards an alternative end-joining pathway. By inhibiting DNA polymerase theta (PolO), Talazoparib further enhances radiosensitization in HR-proficient cancer cells. The study suggests that PolO inhibition could be utilized to maximize the radiosensitization of Talazoparib in treating HR-proficient tumors. [Extracted from the article]

Research from the N.N. Blokhin National Medical Research Center of Oncology explores the impact of germline and somatic alterations in the NBN gene on the development and treatment of malignant neoplasms. The study highlights the role of DNA repair mechanisms in tumor progression and the potential implications for anti-tumor drug resistance. Understanding the functional significance of NBN variants could be crucial in determining treatment strategies for certain types of tumors. For more information, the full article can be accessed for free at the provided link. [Extracted from the article]

A patent has been issued for compositions and methods for detecting nucleic acid regions by inventors from Carlsbad, California. The patent, assigned to Life Technologies Corporation, focuses on detecting off-target effects of engineered nucleases used in genome editing to minimize risks. The methods involve detecting nucleic acid regions within genomic DNA sequences, ranging from 30 bp to 6000 bp in length, and may include foreign genomic fragments or inserted sequences resulting from double-stranded breaks. The patent details a method for detecting off-target insertion of a donor nucleic acid molecule in the genome of a cell, emphasizing the importance of specificity and sensitivity in detecting these genetic modifications. [Extracted from the article]

A study published in Cancer Weekly discusses the potential of using systemic actinium-225 radiopharmaceutical therapy to treat glioblastoma, a type of brain tumor. The study found that dendrimer-radioconjugates labeled with actinium-225 improved survival in mice with glioblastoma, especially when administered after chemotherapy. The therapy showed promise in inhibiting the growth of glioblastoma cells and prolonging survival without causing notable toxicities. The preprint has not yet been peer-reviewed, and more information can be found on biorxiv.org. [Extracted from the article]

Researchers at Hillman Cancer Center in Pittsburgh, Pennsylvania, have developed a method using liquid chromatography-mass spectrometry to quantify the DNA-dependent protein kinase inhibitor Peposertib (M3814) and its metabolite in human plasma. This inhibitor is crucial for DNA repair and cell survival, particularly in cancer treatment. The research, supported by Merck KGaA, aims to define the pharmacokinetics of Peposertib through ongoing clinical studies. The study has been peer-reviewed and published in Biomedical Chromatography, providing valuable insights for future cancer therapies. [Extracted from the article]

Researchers from Chengdu University of Traditional Chinese Medicine have published a report on the mechanisms for repairing sperm DNA damage, highlighting the impact of DNA damage on male infertility and adverse reproductive outcomes. The study emphasizes the importance of understanding DNA repair mechanisms during spermatogenesis, oocytes after fertilization, and early embryonic development stages. The research identifies nucleotide excision repair, base excision repair, mismatch repair, and double-strand break repair as key mechanisms for repairing sperm DNA damage, with proteins like XRCC4-like factor and PAXX playing critical roles in the process. This peer-reviewed study aims to provide a perspective for further research on DNA damage repair mechanisms in spermatozoa. [Extracted from the article]

The article discusses the importance of homologous recombination in repairing DNA double-strand breaks and maintaining genome integrity. Pathogenic mutations in HR proteins like BRCA2 and RAD51 paralogs can increase the risk of certain cancers. Recent studies have shed light on the molecular structures of RAD51 paralog complexes BCDX2 and CX3, revealing interactions with BRCA2 and highlighting the significance of a specific FxxA motif in RAD51B. This research provides valuable insights into the functions of these proteins, although the preprint has not yet undergone peer review. [Extracted from the article]

A study conducted at Renmin Hospital of Wuhan University in China focused on the role of Ubiquitin-Specific Protease 5 (USP5) in tumor development and treatment. USP5 plays a crucial role in various cellular activities and is implicated in the progression of liver, lung, pancreatic, breast cancers, and melanoma. The study explored the mechanisms of action of USP5 and its inhibitors, highlighting their potential as targets for tumor treatment. The research provides insights into the complex regulatory pathways involving USP5 and the development of inhibitors for clinical translation. [Extracted from the article]

The article discusses the impact of mutations in the RPS19 and RPL5 genes on DNA double-strand break repair in Diamond Blackfan anemia (DBA) patients. It highlights how these mutations may lead to defective repair mechanisms, potentially contributing to the increased risk of cancer in individuals with DBA. The study found that RPS19 and RPL5 play crucial roles in different pathways of DNA repair, shedding light on the underlying mechanisms of cancer predisposition in DBA. [Extracted from the article]

The article discusses the use of Zinc Finger Repressors (ZFR) to epigenetically silence immune checkpoints and TGFBR2 in CAR-T cells and tumor-infiltrating lymphocytes (TILs) to enhance anti-tumor activity. The study focuses on overcoming the immunosuppressive tumor microenvironment in solid tumors by repressing PD-1 expression in TILs from colorectal liver metastases. The research suggests that multiplexed ZFRs could be a safer alternative to nucleases for targeting immunosuppressive factors in the tumor microenvironment, potentially improving anti-cancer immunotherapies. [Extracted from the article]

Recent studies from the Institute of Cytology and Genetics of the Siberian Branch of the Russian Academy of Sciences focus on the effects of auxin-dependent degradation of cohesin and condensin complexes on the repair of distant DNA double-strand breaks in mouse embryonic stem cells. The research highlights the role of the SMC protein family in maintaining chromosome structure and influencing cellular processes, particularly DNA repair mechanisms. Contrary to expectations, Rad21 depletion did not increase deletion/inversion frequencies, while double condensin depletion showed high biological variability, requiring further investigation. The study utilized Cas9 RNP nucleofection to generate deletions and inversions efficiently and discussed the Neon/ddPCR method for deletion detection in mESCs. [Extracted from the article]

A patent application has been submitted for a dosing regimen involving the use of a compound called AZD5305, which is a PARP1 inhibitor and DNA trapper. This compound is intended for the treatment of various cancers, including breast, ovarian, pancreas, prostate, hematological, gastrointestinal, and lung cancers. The dosing regimen involves administering AZD5305 in daily doses ranging from 10 to 140 mg, with the aim of providing a more effective and less toxic cancer treatment compared to existing PARP inhibitors. [Extracted from the article]

A patent application titled "Fusion Effector Proteins And Uses Thereof" was published online by inventors GAO, Yuchen; HARRINGTON, Lucas Benjamin; ZHENG, Yuxuan. The application discusses the development of fusion effector proteins for precise genome editing without generating double-stranded DNA breaks. These proteins, such as base editors, transcriptional activators, and transposases, offer potential applications in gene correction and modulation of gene expression. The patent application outlines compositions, systems, and methods for utilizing these fusion effector proteins in genetic research and disease treatment. [Extracted from the article]

A recent study from the School of Public Health focused on the effects of repeated radon exposure on DNA damage response and protective autophagy in mice and human bronchial epithelial cells. The research highlighted the induction of DNA lesions, specifically double-strand breaks, and the activation of ATM-dependent repair pathways and autophagy in response to radon exposure. The findings suggest that ATM-mediated autophagy may play a protective role against radon-induced DNA damage. The study was funded by the National Natural Scientific Foundation of China and published in Toxicology Research. [Extracted from the article]

A recent study conducted at the Montreal Clinical Research Institute (IRCM) in Canada has shed light on the role of protein UFMylation in the early events of ribosomal DNA-damage response in Ataxia Telangiectasia. The research highlights the importance of UFMylation in orchestrating DNA double-strand break repair in human cells, particularly in regulating ATM activation and rDNA transcriptional silencing. This study provides valuable insights into the mechanisms underlying the response to genotoxic stress in neurodegenerative diseases like Ataxia Telangiectasia. [Extracted from the article]

Cells face a high risk of DNA damage during division due to the need to duplicate genetic material, leading to potential errors. Factors like sunlight, alcohol, and cigarettes can also contribute to DNA damage and cancer. Researchers at the University of Wurzburg have identified a new mechanism involving RNA transcripts in the DNA damage response, specifically focusing on NEAT1, which plays a role in genome stability and DNA repair. Understanding NEAT1's function could offer new therapeutic options for tumors with high NEAT1 expression, though further research is needed to validate these findings in complex tumor models. [Extracted from the article]

This article discusses the distinct roles of the two DNA binding domains in the BRCA2 protein in DNA damage repair and replication fork preservation. The BRCA2 protein is important for maintaining genome stability, and mutations in this protein can lead to familial breast, ovarian, and other cancers. The study found that one DNA binding domain, called OB-DBD, is responsible for binding to single-stranded DNA, while the other domain, called CTRB-DBD, is responsible for binding to double-stranded DNA. Mutations in either domain impair the ability of BRCA2 to load the recombinase RAD51 onto single-stranded DNA and protect stressed replication forks. The study concludes that both DNA binding domains are essential for the functions of BRCA2 in genome maintenance. [Extracted from the article]

According to a preprint abstract from biorxiv.org, non-homologous end joining (NHEJ) is necessary for repairing DNA double strand breaks (DSBs) during lymphocyte antigen receptor gene assembly. The senataxin helicase, along with the RECQL5 helicase and the HLTF translocase, plays a redundant role in NHEJ. Loss of senataxin leads to a defect in repairing DSBs when DNA-PKcs is inactivated. The study suggests that ATM and DNA-PKcs regulate the functions of senataxin and RECQL5/HLTF, respectively, to provide redundant support for NHEJ. This research has not yet undergone peer review. [Extracted from the article]

A recent study conducted by researchers at the Van Andel Institute focused on chromatin and the human glycosylase OGG1 enzyme. The study found that OGG1 plays a crucial role in repairing oxidized DNA bases and is involved in various pathological conditions such as cancer and neurodegenerative diseases. The researchers used cryo-EM structures to examine how OGG1 operates on longer DNA and nucleosomes. They discovered that OGG1 preferentially binds near dsDNA ends at nucleosomal entry/exit sites and can also bend the nucleosomal entry DNA and bind to internal nucleosomal DNA sites. The study suggests that OGG1's DNA base search mechanism may be dependent on the chromatin context and that it may work in conjunction with chromatin remodelers to remove oxidized DNA bases. [Extracted from the article]

A recent study conducted by researchers at the University of Lorraine explores the potential of personalized medicine in the treatment of pancreatic ductal adenocarcinoma (PDAC), one of the deadliest cancers. The study focuses on the role of damage-specific DNA binding protein 2 (DDB2) in the response to radiotherapy, with and without the use of the PARP inhibitor olaparib. The findings suggest that low expression of DDB2 may enhance the radiosensitization effect of olaparib, potentially widening the scope of patients who can benefit from this treatment. The research provides valuable insights into the use of DDB2 as a potential biomarker for predicting resistance to radiation and improving the limited use of radiotherapy in PDAC patients. [Extracted from the article]

A recent study conducted at China Medical University in Taichung, Taiwan, has identified potential therapeutic targets for pancreatic cancer. The researchers focused on histone lysine demethylases (KDMs) and found that high expression levels of KDM1A, KDM5A, and KDM5B were associated with improved overall survival in patients with pancreatic cancer. Additionally, the study revealed connections between these genes and immune cell infiltration, as well as various cellular pathways. These findings suggest that KDM1A, KDM5A, and KDM5B may serve as promising biomarkers and therapeutic targets for pancreatic cancer, a disease with a high mortality rate and a need for improved diagnosis and treatment options. [Extracted from the article]

This document is a patent application for a crystalline form of an azetidine PARP1 inhibitor. The application discusses the role of PARP1 in DNA repair and the potential for selective killing of cancer cells through inhibition of PARP enzymes. It describes different crystalline forms of the inhibitor, including their X-ray powder diffraction patterns and thermograms. The inventors claim various crystalline forms of the compound, including different salts and solvates. The application provides detailed information about the different crystalline forms and their characteristics. [Extracted from the article]

The article discusses the CHAMP1 complex, a protein complex consisting of CHAMP1, POGZ, and HP1, which is found in heterochromatin regions of the genome. The function of this complex in these regions is not well understood. However, the study shows that the CHAMP1 complex promotes heterochromatin assembly at various chromosomal sites, including centromeres and telomeres, and also plays a role in homology-directed repair of DNA double strand breaks in these regions. The CHAMP1 complex is also involved in heterochromatin assembly and DNA repair in specialized chromosomal regions, such as the highly-compacted telomeres of ALT positive tumor cells. Individuals with CHAMP1 syndrome, an inherited neurologic disorder, exhibit defective heterochromatin clustering and DNA repair, suggesting that a DNA repair defect may underlie this syndrome. The study highlights the novel role of the CHAMP1 complex in heterochromatin assembly and the enhancement of DNA repair in heterochromatin. [Extracted from the article]

The researchers have submitted a patent application for a method called INDUCE-seq, which allows for the direct measurement of nucleic acid breaks, specifically double-strand breaks (DSBs). DSBs can be harmful to cells and can lead to genome rearrangements and cancer. Current methods for detecting DSBs have limitations, but INDUCE-seq overcomes these limitations by avoiding PCR amplification, providing a more accurate measurement of genomic breaks. The method can be used to understand the origins and repair mechanisms of breaks, as well as for the safe development of genome editing techniques. The patent application provides detailed instructions for preparing a sample to identify DSBs, including modifying the nucleic acids and sequencing them. [Extracted from the article]

A patent application has been filed for a method called INDUCE-seq, which allows for the direct measurement of nucleic acid breaks, specifically double-strand breaks (DSBs). DSBs are hazardous to cells and can lead to genome rearrangements and cancer. Existing methods for detecting DSBs suffer from bias introduced during PCR amplification, which distorts the original pattern of breaks. INDUCE-seq overcomes this drawback by avoiding PCR amplification and providing a direct measurement of genomic breaks. The method can detect both low-level sporadic breaks and higher-level induced breaks, making it useful for understanding break formation and repair mechanisms, as well as for safe genome editing. [Extracted from the article]

A recent study conducted at the University of California has found that increased levels of activation-induced cytidine deaminase (AID) in immature B cells can lead to mutations at the CRLF2 locus, which is associated with a subtype of acute lymphoblastic leukemia (ALL) that disproportionately affects Hispanics, particularly those with Latin American ancestry. The researchers developed a digital PCR assay to quantify these mutations and found increased mutations in both Hispanic ALL patients and healthy Hispanic donors. This research has important implications for risk identification, early detection of cancers, and reducing health disparities in Latin American ALL. [Extracted from the article]

A recent study conducted at the University of Texas Health Science Center has provided new information about cancer and the role of break-induced replication (BIR) in repairing DNA double-strand breaks. BIR is a highly mutagenic process that can lead to chromosomal rearrangements and genetic instabilities associated with human disease. The study discusses the mechanism of BIR, its association with replication stress, and its destabilizing effects on the genome. The researchers also explore the potential for using the BIR machinery to develop anti-cancer therapeutics. This research has been peer-reviewed and offers valuable insights into the understanding and treatment of cancer. [Extracted from the article]

A new report from the Roswell Park Comprehensive Cancer Center in Buffalo, New York, presents fresh data on liver cancer. The study focuses on the RAD51 gene, which is involved in DNA repair. The researchers found that high expression of RAD51 in hepatocellular carcinomas (HCCs) was associated with worse survival and increased cell proliferation. Interestingly, RAD51 expression did not necessarily correlate with immune infiltration or inflammation. This research provides valuable insights into the tumor microenvironment and immune landscape of liver cancer. [Extracted from the article]

A recent study conducted by the National Institutes for Quantum Science and Technology (QST) in Chiba, Japan, has found that a chemically modified catechin analog with a planar structure exhibits enhanced anti-cancer effects compared to the parent catechin. The study focused on a gastric cancer cell line and found that the planar catechin treatment increased the expression of an apoptotic marker, cleaved caspase-3, while reducing the accumulation of reactive oxygen species (ROS) and NF-kB expression. Additionally, the planar catechin treatment induced the marker of double-strand breaks in DNA, gH2AX, in a dose-dependent manner. These findings suggest that the planar catechin's antioxidant ability and its impact on ROS removal, NF-kB suppression, and DNA damage contribute to the induction of apoptosis in cancer cells. [Extracted from the article]

A recent study conducted at the Federal University Rio Grande in Porto Alegre, Brazil, has explored the potential benefits of nanoencapsulation of etoposide, a commonly used chemotherapy drug, in the treatment of lung cancer. The researchers developed etoposide-loaded lipid-core nanocapsules (ETO NC) that demonstrated stability and sustained release of the drug. The study found that ETO NC enhanced the long-term effects of etoposide, inducing DNA damage and senescence in lung cancer cells. The findings suggest that this innovative strategy could overcome the limitations of current treatments and warrant further investigation in animal models. [Extracted from the article]

Researchers from the Erasmus University Medical Center Cancer Institute in Rotterdam, Netherlands, have conducted a study on embryonic stem cells and their role in repairing DNA double strand breaks (DSBs) caused by ionizing radiation. The study found that DSB repair primarily occurs through two pathways: Non-Homologous End Joining (NHEJ) and Homologous Recombination (HR). The researchers generated mouse embryonic stem cells that lacked both NHEJ and HR proteins and found that these cells were hypersensitive to X-ray radiation and had impaired DNA repair. The findings highlight the importance of these pathways in maintaining genomic stability and suggest potential targets for enhancing radiotherapy outcomes. [Extracted from the article]

A recent study conducted at Friedrich-Alexander-University Erlangen-Nurnberg (FAU) in Germany has discovered cancer-associated single-nucleotide polymorphisms (SNPs) in the bacteria Helicobacter pylori. These SNPs have been found to affect cancer risk by modifying inflammatory responses, loss of host cell polarity, and introducing DNA double-strand breaks in host chromosomes. The researchers suggest that further investigation into these SNPs in bacteria is necessary. This research has been peer-reviewed and published in Trends in Microbiology. [Extracted from the article]

A recent study conducted at Ohio State University has reported new findings in the field of leukemia research. The study focused on the use of CRISPR/Cas9 gene-editing technology to disrupt the production of a specific enzyme, TOP2/3/180, which is involved in DNA topology regulation. The researchers found that the disruption of TOP2/3/180 expression resulted in partial to complete loss of the enzyme, leading to changes in drug sensitivity and resistance in leukemia cells. The study highlights the importance of TOP2/3/180 in drug response and provides insights into the activity of targeted agents. [Extracted from the article]